Last month, the preliminary results of a German study were released that suggest stroke patients who take certain anti-anemia drugs increase their chances of dying. The U.S. Food and Drug…
Read More
One of the most difficult Effexor-related birth defects is the condition known as Persistent Pulmonary Hypertension of the Newborn (PPHN). Described briefly, PPHN results in the infant being unable to…
Read More
There is a perception among pharmaceutical companies and other corporate defendants that federal courts are friendlier to their interests than state courts. When they are being sued over a dangerous…
Read More
It’s not unusual in pharmaceutical injury lawsuits for many similar cases from around the United States to be consolidated in front of one judge. These multi-district litigation cases are a…
Read More
The FDA is requiring changes in label for gadolinium-based contrast agents (GBCAs) to minimize the risk of nephrogenic systemic fibrosis (NSF), a rare, but serious, condition associated with the use…
Read More
I wrote here last week about the problems with Fosamax (alendronate sodium), a drug prescribed mainly to people suffering from osteoporosis or who are at high risk for osteoporosis. This…
Read More
According to a new study, three hours of therapy in school may help reduce the onset of depression and other mental disorders in teens. The study originally was intended to…
Read More
In the past few years, the U.S. Supreme Court has made life even tougher for victims of injuries caused by generic prescription drugs. In PLIVA v. Mensing, the Court barred…
Read More
I’ve written much on this blog about the terrible consequences of the U.S. Supreme Court’s ruling in PLIVA v. Mensing. In that case, the Court found that victims of injuries…
Read More
I’ve written here before about the problems with illegal marketing of dangerous prescription drugs. Prescription drug makers eager to rake in profits have been caught promoting their drugs for off-label…
Read More